Standard BioTools (NASDAQ:LAB – Get Free Report) and Hims & Hers Health (NYSE:HIMS – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.
Volatility and Risk
Standard BioTools has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500.
Profitability
This table compares Standard BioTools and Hims & Hers Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Standard BioTools | -59.39% | -11.21% | -8.51% |
| Hims & Hers Health | 5.47% | 22.48% | 7.02% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Standard BioTools | 1 | 2 | 0 | 0 | 1.67 |
| Hims & Hers Health | 1 | 13 | 3 | 0 | 2.12 |
Standard BioTools currently has a consensus target price of $1.35, indicating a potential upside of 48.17%. Hims & Hers Health has a consensus target price of $31.71, indicating a potential upside of 60.71%. Given Hims & Hers Health’s stronger consensus rating and higher probable upside, analysts plainly believe Hims & Hers Health is more favorable than Standard BioTools.
Institutional & Insider Ownership
53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by insiders. Comparatively, 13.7% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Standard BioTools and Hims & Hers Health”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Standard BioTools | $85.33 million | 4.16 | -$74.90 million | ($0.20) | -4.56 |
| Hims & Hers Health | $2.35 billion | 1.92 | $128.37 million | $0.51 | 38.69 |
Hims & Hers Health has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Summary
Hims & Hers Health beats Standard BioTools on 12 of the 14 factors compared between the two stocks.
About Standard BioTools
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
About Hims & Hers Health
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
